Lexicon Pharmaceuticals | LXRX - Operating Profit


Lexicon Pharmaceuticals reported $-14.78M in Operating Profit for its fiscal quarter ending in December of 2025.





Operating Profit Change Date
Abbott USD 2.13B 281M Jun/2026
Acadia Pharmaceuticals USD 37.84M 42.45M Jun/2026
Agios Pharmaceuticals USD -110.02M 11.55M Mar/2026
Akebia Therapeutics USD -5.45M 9.4M Dec/2025
Alnylam Pharmaceuticals USD 112.6M 24.99M Jun/2026
AstraZeneca USD 3.16B 3.95B Jun/2026
BioMarin Pharmaceutical USD 105.6M 24.04M Jun/2026
Coherus Biosciences USD -39.08M 3.65M Dec/2025
Eli Lilly USD 12.46B 2.68B Jun/2026
Halozyme Therapeutics USD -63.72M 1.95M Jun/2026
Illumina USD 260M 21M Jun/2026
Insmed USD -101.31M 98.97M Jun/2026
Ironwood Pharmaceuticals USD 33.22M 7.58M Dec/2024
J&J USD 7.48B 860M Jun/2026
Lexicon Pharmaceuticals USD -14.78M 2.59M Dec/2025
MacroGenics USD -33.44M 21.34M Mar/2026
MannKind USD -68.23M 8.76M Jun/2026
Merck USD 840M 2.72B Jun/2026
Moderna USD -815M 573M Jun/2026
Novartis USD 4.75B 515M Jun/2026
PTC Therapeutics USD 45.89M 127.51M Mar/2026
Puma Biotechnology USD 22.08M 24.26M Sep/2024
Sarepta Therapeutics USD 13.29M 345.14M Jun/2026
Thermo Fisher Scientific USD 2.18B 273M Jun/2026
Ultragenyx Pharmaceutical USD -75M 141M Jun/2026
United Therapeutics USD 330.8M 5M Jun/2026
Vanda Pharmaceuticals USD -40.66M 29.66M Dec/2024